Page 12 - வரைபடம் மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Blueprint Medicines: Geht es jetzt um die Wurst? ()
aktiencheck.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aktiencheck.de Daily Mail and Mail on Sunday newspapers.
Roche-Partner Blueprint Medicines: Hier passt einfach alles zusammen
deraktionaer.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from deraktionaer.de Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines: Was jetzt noch richtig spannend wird … ()
aktiencheck.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aktiencheck.de Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Dec. 17, 2020 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for AYVAKIT™ (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis (SM). AYVAKIT is a potent and selective inhibitor of D816V mutant KIT, the primary driver of SM, and is being developed to treat advanced and non-advanced forms of the disease.